Shares of Athira Pharma climbed Monday morning as an analysis of un-blinded interim data showed its Alzheimer’s drug candidate, fosgonimeton, provided clinically meaningful improvements in cognition and function. Bothell, Washington-based Athira shared data that showed an analysis of about 100 patients in the Phase II/III LIFT-AD study saw these improvements. The data informed Athira of the necessary sample size […]

It’s not the best economic environment for consumer-driven digital health businesses. This has caused some organizations to accelerate a shift toward a business-to-business (B2B) strategy, experts say. In its second quarter earnings call, executives at New York City-based digital health company DarioHealth said they were lessening the focus on its legacy direct-to-consumer business.

It’s not the best economic environment for consumer-driven digital health businesses. This has caused some organizations to accelerate a shift toward a business-to-business (B2B) strategy, experts say. In its second quarter earnings call, executives at New York City-based digital health company DarioHealth said they were lessening the focus on its legacy direct-to-consumer business.